

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549  
FORM 8-K  
CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the  
Securities Exchange Act of 1934**

**Date of Report (Date of earliest event reported): April 18, 2019**

**KALVISTA PHARMACEUTICALS, INC.**

(Exact name of registrant as specified in its charter)

Delaware

(State or other jurisdiction of incorporation)

Delaware  
(State or Other Jurisdiction  
of Incorporation)

001-36830  
(Commission  
File Number)

20-0915291  
(IRS Employer  
Identification No.)

55 Cambridge Parkway  
Suite 901E

Cambridge, Massachusetts 02142  
(Address of Principal Executive Offices) (Zip Code)

(857) 999-0075

(Registrant's telephone number, including area code)

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards pursuant to Section 13(a) of the Exchange Act.

---

**Item 5.02(d)**

On April 18, upon the recommendation of the Nominating and Governance Committee of the Board of Directors ("**Board**") of KalVista Pharmaceuticals, Inc. (the "**Company**"), the Board approved the appointment of Daniel B. Soland ("**Mr. Soland**") to the Board effective April 22, 2019. Mr. Soland will serve as a Class II Director whose term will expire at the Company's 2020 Annual Meeting of Stockholders when the Class II Directors will next be elected by the Company's stockholders.

There are no arrangements or understandings between Mr. Soland and any other persons pursuant to which Mr. Soland was named as a director. Mr. Soland is not a party to any transaction required to be disclosed pursuant to Item 404(a) of Regulation S-K.

Mr. Soland's compensation shall be consistent with the Company's policy for incoming non-employee directors, which provides for (i) an initial award upon such individual's first appointment to the Board, consisting of options to purchase 14,000 shares of the Company's common stock and (ii) \$40,000 paid in cash.

In connection with his appointment to the Board, Mr. Soland will execute the Company's standard form of indemnification agreement for directors.

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**KALVISTA PHARMACEUTICALS, INC.**

Date: April 24, 2019

By: /s/ Benjamin L. Palleiko  
Benjamin L. Palleiko  
Chief Business Officer and Chief Financial Officer